Bioporto A/S logo

BIOPOR - Bioporto A/S News Story

DKK3.59 -0.1  -3.0%

Last Trade - 18/06/21

Sector
Industrials
Size
Small Cap
Market Cap £111.1m
Enterprise Value £102.3m
Revenue £2.84m
Position in Universe 884th / 1844

Peter Mørch Eriksen resigns as CEO of BioPorto A/S

Wed 5th May, 2021 6:47pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210505:nGNE5J9BVD&default-theme=true


May 5, 2021
Announcement no. 10

Peter Mørch Eriksen resigns as CEO of BioPorto A/S

After having led BioPorto as CEO for almost 8 years, BioPorto’s Chief
Executive Officer, is resigning his position as CEO of the Company. Peter will
continue to support the Company until end of January 2022, and will retain his
position as CEO until his successor has been found.

Peter Mørch Eriksen says: “It is, and has been, a privilege to be CEO of
BioPorto, and I look forward to continue to support the Company’s ongoing
projects, including the clinical studies and expected submission this summer
of a De Novo application to the FDA for pediatric use of The NGAL Test™.
Considering the important milestones ahead for BioPorto, I find this to be the
right time to find my successor who can lead the Company into its next
phase.”

Thomas Magnussen, Chairman of the Board of Directors, says: “I wish to thank
Peter for his tremendous efforts for the Company over many years. I and the
rest of the organization look forward to continue working with Peter over the
coming months, as we proceed to identify and appoint his successor and further
advance the ongoing transition of the Company to the North American market.”

For further information, please contact:

Thomas Magnussen, Chairman of the Board

Telephone +45 3177 0000, e-mail: investor@bioporto.com

About BioPorto

BioPorto is an in vitro diagnostics company that provides tests and antibodies
to clinicians and researchers around the world. We use our antibody and assay
expertise to transform novel research tools into clinically actionable
biomarkers that can make a difference in patients’ lives. BioPorto is
headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen
stock exchange  CPH:BIOPOR .


Attachment
*     2021 05 05 - Company announcement no. 10
(https://ml-eu.globenewswire.com/Resource/Download/9c6c2ec0-b8da-40a1-9576-53d93d049d36)
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.